| Autor: |
Stephenson, C. M. E., Bigliani, V., Jones, H. M., Mulligan, R. S., Acton, P. D., Visvikis, D., Ell, P. J., Kerwin, R. W., Pilowsky, L. S. |
| Předmět: |
|
| Zdroj: |
British Journal of Psychiatry; Nov2000, Vol. 177, p408-415, 8p, 1 Chart, 1 Graph |
| Abstrakt: |
Background Selective action at limbic cortical dopamine D2-like receptors could mediate atypical antipsychotic efficacy with few extrapyramidal side-effects. Aims To test the hypothesis that quetiapine has ‘limbic selective’ D2/D3 receptor occupancy in vivo. Method The high-affinity D2/D3 ligand [123I]-epidepride and single photon emission tomography were used to estimate D2/D3 specific binding and an index of relative percentage D2/D3 occupancy in striatal and temporal cortical regions for quetiapine-treated patients (n=6). Quetiapine-, and previously studied typical-antipsychotic- and clozapine-treated patients were compared. Results Mean (s.d.) relative percentage D2/D3 receptor occupancy by quetiapine was 32.0% (14.6) in striatum and 60.1% (17.2) in temporal cortex (mean daily dose 450 mg: range 300-700 mg/day). Quetiapine treatment resulted in limbic selective D2/D3 blockade similar to clozapine and significantly higher than typical antipsychotics. Conclusions Preliminary data suggest that limbic selective D2/D3 receptor blockade is important for atypical drug action. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
